anti cancer medicine

Sutib 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Oncology Care Sutib 12.5 mg Capsule is a high-potency oral therapeutic agent containing the active substance Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutib is a cornerstone in modern targeted cancer therapy. Manufactured by Cadila Pharmaceuticals (Zydus), it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Sutib 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often as a first-line therapy to improve progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Indicated for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy) in high-risk patients. Mechanism of Action: How Sutib 12.5mg Works Sutib works through a dual-mechanism approach to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutib 12.5 mg is an oral medication. Capsules should be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (37.5 mg or as adjusted) without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state levels. Safety Profile and Clinical Monitoring Treatment with Sutib 12.5 mg requires vigilant medical oversight for: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutib 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Malignancies Sutib 12.5 mg Capsule is a high-efficacy oral antineoplastic agent featuring the active pharmaceutical ingredient Sunitinib Malate. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutib is a cornerstone in modern precision oncology. Manufactured by Cadila Pharmaceuticals (Zydus), it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 28-capsule pack is the standard clinical format, meticulously dosed to facilitate the complex “on-off“ cycles required for effective tumor suppression. Therapeutic Indications and Global Clinical Usage Sutib 12.5mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sutib 12.5mg Works Sutib employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Pack Size: 28 Capsules per Bottle/Box. Administration: Sutib 12.5mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (37.5mg or adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sutib 12.5 mg requires consistent medical oversight to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutykine 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Oncology Care Sutykine 12.5 mg Capsule is a high-potency oral therapeutic agent containing the active substance Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutykine is a cornerstone in modern targeted cancer therapy. Manufactured by Zuventus Healthcare, it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Sutykine 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often as a first-line therapy. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Indicated for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy). Mechanism of Action: How Sutykine 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutykine helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutykine 12.5 mg is an oral medication. Capsules should be swallowed whole with water. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off. Continuous Regimen (pNET): Often prescribed as a continuous daily dose without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration (e.g., 25 mg, 37.5 mg, or 50 mg) based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day. Safety Profile and Clinical Monitoring Treatment with Sutykine 12.5 mg requires vigilant medical oversight for: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Pancreatic Health: Periodic blood tests to check liver enzymes and lipase levels are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or “hand-foot syndrome,“ which should be managed by the oncology team. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Svitinib 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Cancer Therapy Svitinib 12.5mg Capsule is a potent, oral multi-kinase inhibitor featuring the active pharmaceutical ingredient Sunitinib. It belongs to a sophisticated class of medications known as tyrosine kinase inhibitors (TKIs). Manufactured by Sun Pharma, a global leader in high-quality pharmaceuticals, Svitinib is engineered to interfere with the growth and spread of cancer cells by blocking specific enzymes that promote tumor vascularization and cellular proliferation. Therapeutic Indications and Clinical Usage Svitinib 12.5mg is a cornerstone in international oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Used as a first-line treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In certain regions, it is utilized as an adjuvant treatment for adult patients at high risk of recurrent RCC following nephrectomy. Mechanism of Action: How Svitinib 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By doing so, it “starves“ the tumor by preventing the formation of new blood vessels. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid division of malignant cells. Metastasis Inhibition: By disrupting these signaling pathways, Svitinib helps reduce the ability of the cancer to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical schedule involves a “4 weeks on, 2 weeks off“ cycle. The dose may be adjusted based on clinical response and tolerability. Continuous Regimen (pNET): For pancreatic neuroendocrine tumors, a continuous daily dose (without a rest period) is often prescribed. Method of Intake: Capsules should be swallowed whole with water. They can be taken with or without food. Consistency: It is recommended to take the medication at the same time each day to maintain stable plasma concentrations. Safety Profile and Professional Monitoring Treatment with Svitinib 12.5mg requires consistent medical oversight to manage potential adverse effects: Hypertension Monitoring: Blood pressure should be monitored regularly, as Sunitinib can cause significant increases. Hematological Checks: Regular Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect. Skin and Hair Changes: Patients may notice skin discoloration (yellowing) or hair depigmentation during the treatment cycles. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is essential. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or trained caregivers. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celomide 5mg Capsule (Lenalidomide): Precision Maintenance Therapy for Hematological Oncology. Celomide 5 mg Capsule is a specialized, low-dose immunomodulatory medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 5 mg strength is a critical dosage form used primarily for maintenance therapy, dose tapering, and patients requiring renal dose adjustments. Manufactured by Celon Laboratories Pvt. Ltd., Celomide 5mg is an essential component in the long-term management of hematological malignancies, providing a balance between therapeutic efficacy and manageable toxicity. Therapeutic Indications and Clinical Usage Celomide 5 mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM) Maintenance: Following an autologous stem cell transplant (ASCT) or induction therapy, the 5 mg dose is often used as a long-term maintenance strategy to prevent disease relapse. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Renal Dose Adjustments: For patients with moderate to severe renal impairment, the 5 mg capsule allows for precise dosing to maintain efficacy while reducing the risk of systemic toxicity. Relapsed/Refractory Lymphoma: Used in combination with other agents for patients with Mantle Cell Lymphoma (MCL) or Follicular Lymphoma who require a lower starting dose or a dose reduction. Mechanism of Action: How Celomide 5mg Works Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex, leading to the selective degradation of transcription factors (Ikaros and Aiolos) necessary for cancer cell survival. Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors (like VEGF), preventing the tumor from forming the new blood vessels it needs to grow. Immune Surveillance: It enhances the activity of T-cells and Natural Killer (NK) cells, boosting the body’s innate ability to find and destroy residual cancer cells. Cytokine Modulation: It inhibits the production of pro-inflammatory cytokines like TNF-α, which otherwise support the survival of malignant cells in the bone marrow microenvironment. Dosage and Administration Guidelines Maintenance Dosing: In maintenance settings, Celomide 5mg is often taken once daily on a continuous basis or following a “21 days on, 7 days off“ cycle. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Escalation/De-escalation: The 5 mg strength provides oncologists with the flexibility to titrate the dose upward as tolerated or downward to manage hematological toxicities. Safety Profile and Clinical Monitoring Low-dose therapy still requires vigilant professional oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are required to monitor for neutropenia and thrombocytopenia, though these are typically less frequent at the 5 mg level than at higher doses. Thromboembolism Prophylaxis: Even at 5 mg, there remains a risk of blood clots (DVT/PE). Anticoagulant therapy (e.g., Aspirin) is frequently continued during maintenance. Embryo-Fetal Toxicity (REMS): Lenalidomide remains a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of dosage. General Side Effects: Patients may experience mild fatigue, diarrhea, or skin rashes. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep the capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Laviat 5 mg Capsule (Lenalidomide): Precision Immunotherapy for Long-Term Oncology Care Laviat 5 mg Capsule is a high-efficacy, low-dose immunomodulatory medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 5 mg strength is a vital therapeutic tool used primarily for maintenance therapy, precise dose titration, and treatment regimens for patients with specific renal considerations. Manufactured by Fresenius Kabi Oncology Ltd., Laviat 5mg provides a strategic balance between controlling malignant cell proliferation and maintaining a high quality of life for the patient. Therapeutic Indications and Clinical Usage Laviat 5mg is integrated into global oncology protocols for the management of: Multiple Myeloma (MM) Maintenance: Used as a long-term strategy following autologous stem cell transplant (ASCT) to prolong progression-free survival and prevent disease relapse. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Used for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Often used in combination with Rituximab for adult patients previously treated for follicular or marginal zone lymphoma. Mechanism of Action: How Laviat 5mg Works Cereblon Binding: It binds to the protein Cereblon, a component of the E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors required for cancer cell survival. Immune System Activation: It stimulates T-cells and Natural Killer (NK) cells, significantly increasing the body's natural ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the development of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-$alpha$ and IL-6, which are known to promote the growth of myeloma cells in the bone marrow microenvironment. Dosage and Administration GuidelinesMaintenance Regimen: The 5 mg dose is frequently taken once daily, often on a cycle of “21 days on, 7 days off“ or as a continuous daily dose depending on the protocol. Administration: Capsules must be swallowed whole with water. Do not open, crush, or chew them. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma levels. Dose Flexibility: The 5 mg strength allows oncologists to de-escalate dosage from 25 mg or 15 mg strengths to manage hematological toxicities effectively. Safety Profile and Clinical Monitoring Medical supervision is mandatory while taking Laviat 5mg: Hematological Vigilance: Regular Complete Blood Counts (CBC) are necessary to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Most patients are prescribed concurrent anticoagulants (blood thinners). Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of the dose. Common Side Effects: Fatigue, diarrhea, muscle cramps, and skin rashes are frequently reported and managed with supportive care. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately with soap and water. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lendomy 5mg Capsule (Lenalidomide): Precision Maintenance Therapy for Hematological Oncology Lendomy 5mg Capsule is a specialized, low-dose immunomodulatory medication featuring the active pharmaceutical ingredient Lenalidomide. As a potent immunomodulatory imide drug (IMiD), the 5mg strength is a critical dosage form used primarily for maintenance therapy, dose tapering, and patients requiring renal dose adjustments. Manufactured by Mylan (Viatris), Lendomy 5mg is an essential component in the long-term management of hematological malignancies, providing a balance between therapeutic efficacy and manageable toxicity. Therapeutic Indications and Clinical Usage Lendomy 5mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM) Maintenance: Following an autologous stem cell transplant (ASCT) or induction therapy, the 5mg dose is often used as a long-term maintenance strategy to prevent disease relapse and extend progression-free survival. Myelodysplastic Syndromes (MDS): Specifically indicated for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Renal Dose Adjustments: For patients with moderate to severe renal impairment, the 5mg capsule allows for precise dosing to maintain efficacy while reducing the risk of systemic toxicity. Relapsed/Refractory Lymphoma: Used in combination with other agents for patients with Mantle Cell Lymphoma (MCL) or Follicular Lymphoma who require a lower starting dose or a dose reduction. Mechanism of Action: How Lendomy 5mg Works Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex, leading to the selective degradation of transcription factors (Ikaros and Aiolos) necessary for cancer cell survival.Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors (like VEGF), preventing the tumor from forming the new blood vessels it needs to grow.Immune Surveillance: It enhances the activity of T-cells and Natural Killer (NK) cells, boosting the body’s innate ability to find and destroy residual cancer cells. Cytokine Modulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$, which otherwise support the survival of malignant cells in the bone marrow microenvironment. Dosage and Administration Guidelines Maintenance Dosing: In maintenance settings, Lendomy 5 mg is often taken once daily on a continuous basis or following a “21 days on, 7 days off“ cycle as directed by an oncologist. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations.Dose Titration: The 5 mg strength provides oncologists with the flexibility to titrate the dose upward as tolerated or downward to manage hematological toxicities.Safety Profile and Clinical MonitoringLow-dose therapy still requires vigilant professional oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are required to monitor for neutropenia and thrombocytopenia. Thromboembolism Prophylaxis: Even at 5 mg, there remains a risk of blood clots (DVT/PE). Anticoagulant therapy (e.g., Aspirin) is frequently continued during maintenance. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of dosage. General Side Effects: Patients may experience mild fatigue, diarrhea, or skin rashes. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep the capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenmid 5mg Capsule (Lenalidomide): Precision Maintenance Therapy for Hematological Oncology Lenmid 5mg Capsule is a specialized, low-dose immunomodulatory medication containing the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 5 mg strength is a cornerstone of long-term cancer management. It is primarily utilized for maintenance therapy and dose-adjusted regimens for patients requiring a balanced approach between clinical efficacy and toxicity management. Manufactured by Cipla, a global pharmaceutical leader, Lenmid 5mg is essential for sustaining remission in various blood-related malignancies. Therapeutic Indications and Clinical Usage Lenmid 5mg is utilized across major international oncology protocols for: Multiple Myeloma (MM) Maintenance: Following an autologous stem cell transplant (ASCT) or induction therapy, the 5 mg dose is the standard for long-term maintenance to prevent disease recurrence. Myelodysplastic Syndromes (MDS): Specifically indicated for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Used as a treatment for patients whose disease has relapsed or progressed after at least two prior therapies. Renal Dose Adjustments: For patients with moderate-to-severe renal impairment, the 5 mg capsule allows for precise titration to maintain therapeutic levels without overwhelming the kidneys. Mechanism of Action: How Lenmid 5mg Works Immune System Modulation: It enhances the activity of T-cells and Natural Killer (NK) cells, significantly boosting the body's innate ability to identify and destroy residual cancer cells. Anti-Angiogenesis: It inhibits the secretion of pro-angiogenic factors (like VEGF), effectively blocking the formation of new blood vessels that tumors need to grow. Direct Tumoricidal Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) specifically in malignant hematopoietic cells. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-$alpha$ and IL-6, which are known to promote the growth of myeloma cells. Dosage and Administration Guidelines Maintenance Protocol: In maintenance settings, Lenmid 5 mg is typically taken once daily, often on a “21 days on, 7 days off“ cycle or as a continuous daily dose. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Professional Titration: Oncologists may adjust the dose from higher strengths (25 mg or 15 mg) down to 5 mg based on patient tolerance and hematological response. Safety Profile and Clinical Monitoring Due to its immunomodulatory nature, Lenmid 5 mg requires consistent medical oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Most patients are prescribed concurrent blood thinners (anticoagulants) such as aspirin or warfarin. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of the dose. Common Side Effects: Fatigue, diarrhea, muscle cramps, and skin rashes are frequently reported and managed with supportive care. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should handle the capsules with care; avoid skin contact if a capsule is accidentally broken. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Carfizome 60mg Injection (Carfilzomib): Targeted Proteasome Inhibition for Advanced Multiple Myeloma. Carfizome 60mg Injection is a high-potency antineoplastic biological therapy featuring the active pharmaceutical ingredient Carfilzomib. As a second-generation proteasome inhibitor, Carfizome 60mg represents a major clinical advancement in the treatment of plasma cell malignancies. It is specifically engineered to provide a more targeted, irreversible binding mechanism compared to first-generation inhibitors, ensuring a deeper and more durable clinical response for patients with relapsed or refractory disease. Therapeutic Indications and Clinical Usage Carfizome 60mg is a cornerstone in international oncology protocols for: Relapsed or Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least one to three prior lines of therapy. Combination Regimens: Frequently prescribed in synergy with Dexamethasone or a combination of Lenalidomide and Dexamethasone to maximize progression-free survival (PFS). Targeted Intervention: It is the preferred choice for patients who have shown resistance to earlier proteasome inhibitors like bortezomib, offering a path forward in complex treatment journeys. Mechanism of Action: How Carfizome 60mg Works Irreversible Proteasome Blockade: Carfilzomib binds irreversibly to the 20S proteasome, the enzyme complex responsible for degrading unwanted or damaged proteins within the cell. Proteotoxic Stress: By blocking this “waste disposal“ system, Carfizome causes a rapid, toxic buildup of polyubiquitinated proteins. Induction of Apoptosis: This internal protein overload triggers a massive cellular stress response, leading directly to apoptosis (programmed cell death) in malignant plasma cells. Selective Potency: Because myeloma cells produce large volumes of antibodies (proteins), they are uniquely sensitive to this mechanism, allowing for targeted destruction with minimized damage to healthy cells. Dosage and Administration Guidelines Administration: Carfizome 60mg is administered strictly as an intravenous (IV) infusion by clinical professionals. Infusion Duration: The procedure typically takes between 10 to 30 minutes, depending on the specific cycle and patient tolerance. Cycle Schedule: Administered in 28-day cycles, usually on two consecutive days each week for three weeks, followed by a 12-day rest period. Hydration Protocol: Adequate hydration (both oral and IV) is mandatory before and after the dose to protect kidney function and prevent Tumor Lysis Syndrome (TLS). Safety Profile and Professional Monitoring Treatment with Carfizome 60mg requires consistent medical oversight for: Cardiac and Pulmonary Health: Monitoring for signs of heart failure, hypertension, or acute respiratory distress. Renal Monitoring: Regular serum creatinine checks are vital to ensure the kidneys are processing the medication effectively. Hematological CBC: Periodic blood counts are necessary to monitor for potential thrombocytopenia (low platelets) or anemia. Common Side Effects: Fatigue, nausea, fever, and headache are frequently reported and managed with supportive care. Strict Cold-Chain Storage & Global Handling Temperature Sensitivity: Carfizome is a biological product and MUST be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Light Protection: Vials should be kept in the original carton to prevent degradation from light exposure. Global Transit Security: For international export, specialized thermal packaging and real-time temperature loggers are used to ensure the medication remains potent and safe during transit to the USA, UK, UAE, Australia, and beyond. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Carzomib 60mg Injection (Carfilzomib): Advanced Proteasome Inhibition for Relapsed Multiple Myeloma. Carzomib 60mg Injection is a high-potency antineoplastic biological therapy featuring the active ingredient Carfilzomib. Classified as a second-generation proteasome inhibitor, Carzomib is a vital therapeutic intervention for patients diagnosed with multiple myeloma. Manufactured by Hetero Healthcare, one of India’s most trusted pharmaceutical giants, Carzomib 60mg is engineered to provide a more targeted, irreversible binding mechanism that enhances anti-tumor activity while offering a manageable safety profile. Therapeutic Indications and Clinical Usage Carzomib 60mg is utilized globally in advanced oncology settings for: Relapsed or Refractory Multiple Myeloma (RRMM): Specifically for adult patients who have received at least one to three prior lines of therapy. Combination Regimens: Often used in combination with Dexamethasone or a combination of Lenalidomide and Dexamethasone to improve progression-free survival (PFS). Targeted Intervention: It is preferred for patients who have shown resistance to first-generation proteasome inhibitors like bortezomib. Mechanism of Action: How Carzomib 60mg Works Proteasome Blockade: Carfilzomib binds irreversibly to the 20S proteasome, the enzyme complex responsible for degrading unwanted or damaged proteins within the cell. Protein Accumulation: By inhibiting this “waste disposal“ system, Carzomib causes a rapid, toxic buildup of polyubiquitinated proteins. Programmed Cell Death: This internal protein overload triggers a massive cellular stress response, leading directly to apoptosis (cell death) in malignant plasma cells. Irreversible Binding: Unlike earlier treatments, the irreversible nature of Carzomib ensures a more prolonged and potent suppression of tumor growth. Dosage and Administration Guidelines Administration: Carzomib 60 mg is administered strictly as an intravenous (IV) infusion by clinical experts. Infusion Duration: The procedure typically takes between 10 and 30 minutes, depending on the specific cycle and patient tolerance. Treatment Cycle: Administered in 28-day cycles, usually on two consecutive days each week for three weeks, followed by a 12-day rest period. Hydration Protocol: Adequate oral and IV hydration is mandatory before and after the dose to protect renal function and prevent Tumor Lysis Syndrome (TLS). Safety Profile and Professional Monitoring Cardiac & Pulmonary Health: Monitoring for signs of heart failure, hypertension, or acute respiratory distress. Renal Monitoring: Regular serum creatinine checks are vital to ensure the kidneys are processing the medication effectively. Hematological CBC: Periodic blood counts are necessary to monitor for potential thrombocytopenia (low platelets) or anemia. Common Side Effects: Fatigue, nausea, fever, and headache are frequently reported and managed with supportive care. Strict Cold-Chain Storage & Global Handling Temperature Sensitivity: Carzomib is a biological product and MUST be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Light Protection: Vials should be kept in the original carton to prevent degradation from light exposure. Global Transit Security: For international export, we utilize validated thermal packaging and real-time temperature loggers to ensure the medication remains potent and safe during transit to the USA, UK, UAE, Australia, and beyond. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Kyfil 60mg Injection (Carfilzomib): Advanced Proteasome Inhibitor for Refractory Multiple Myeloma Kyfil 60mg Injection is a high-potency antineoplastic agent containing the active pharmaceutical ingredient. Carfilzomib. As a second-generation proteasome inhibitor, Kyfil 60mg is a cornerstone in modern hematological oncology, specifically engineered to overcome resistance in patients with multiple myeloma. Manufactured by Biocon, a global biopharmaceutical leader, Kyfil provides a targeted mechanism to disrupt cancer cell survival while minimizing the peripheral neuropathy often associated with earlier treatments. Therapeutic Indications and Clinical Usage Kyfil 60mg is utilized in international oncology centers for the management of aggressive blood cancers: Relapsed or Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least one to three prior lines of therapy. Combination Therapy: Frequently prescribed in combination with Dexamethasone (Kd regimen) or with both Lenalidomide and Dexamethasone (KRd regimen) to maximize clinical response rates. Monotherapy: Used as a standalone treatment for patients whose disease has progressed after receiving at least two prior therapies, including bortezomib and an immunomodulatory agent. Mechanism of Action: How Kyfil 60mg Works Irreversible Inhibition: Carfilzomib binds irreversibly to the 20S proteasome, the enzyme complex responsible for degrading damaged or unneeded proteins within the cell. Protein Overload: By blocking the proteasome, Kyfil causes a toxic buildup of “junk“ proteins inside the myeloma cell. Apoptosis Induction: This protein accumulation triggers a massive cellular stress response, leading directly to apoptosis (programmed cell death). High Selectivity: Kyfil is designed to be more selective for the proteasome than first-generation inhibitors, which contributes to its improved safety profile regarding nerve damage. Dosage and Administration Guidelines Route of Administration: Kyfil 60mg is administered strictly as an intravenous (IV) infusion. Infusion Duration: The infusion usually lasts between 10 and 30 minutes, depending on the specific dosage and cycle. Cycle Schedule: Typically administered on two consecutive days each week for three weeks, followed by a 12-day rest period (a 28-day cycle). Hydration Protocol: To prevent renal toxicity and Tumor Lysis Syndrome (TLS), patients must be adequately hydrated (both oral and IV) before and after the dose. Safety Profile and Clinical Monitoring Cardiac Monitoring: Patients should be monitored for new or worsening heart failure or myocardial ischemia. Respiratory Vigilance: Any shortness of breath should be reported immediately, as Kyfil can occasionally cause pulmonary hypertension or acute respiratory distress. Renal Function: Regular monitoring of serum creatinine levels is mandatory to ensure kidney health during treatment. Hematological CBC: Regular blood counts are necessary to monitor for thrombocytopenia (low platelets) and neutropenia. Storage and Global Handling (Cold Chain) Temperature Control: Kyfil 60 mg vials MUST be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Handling: Do not freeze. Keep the vial in the original carton to protect it from light. Reconstitution: Once reconstituted, the solution should be used immediately or stored refrigerated for a very short duration as per clinical guidelines. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Kyprolis 60mg Injection (Carfilzomib): The Gold Standard Proteasome Inhibitor for Multiple Myeloma Kyprolis 60 mg Injection is a sophisticated antineoplastic agent containing the active substance Carfilzomib. As a second-generation proteasome inhibitor, Kyprolis is engineered for higher selectivity and more potent anti-tumor activity compared to earlier treatments. Manufactured by Amgen, it is a vital therapeutic intervention for patients with multiple myeloma, particularly those who have developed resistance to other therapies. Therapeutic Indications and Clinical Usage Kyprolis 60 mg is a cornerstone in international hematological oncology for the treatment of: Relapsed or Refractory Multiple Myeloma (RRMM): Specifically for adult patients who have received one to three prior lines of therapy. Combination Regimens: * Kd Regimen: Combined with Dexamethasone. KRd Regimen: Combined with Lenalidomide and Dexamethasone. DKd Regimen: Combined with Daratumumab and Dexamethasone. Superior Progression-Free Survival: Clinical trials have demonstrated that Kyprolis-based regimens significantly extend survival compared to standard-of-care treatments in relapsed settings. Mechanism of Action: How Kyprolis 60mg Works Irreversible Proteasome Binding: Carfilzomib binds irreversibly to the chymotrypsin-like activity of the 20S proteasome. Inhibition of Protein Degradation: The proteasome is the cell's “shredder“ for damaged proteins. Blocking it causes an immediate, toxic buildup of polyubiquitinated proteins. Induction of Apoptosis: Myeloma cells produce vast amounts of protein (M-protein); when their “waste disposal“ is blocked, they experience overwhelming cellular stress, leading to programmed cell death (apoptosis). Targeted Efficiency: Kyprolis is designed to minimize off-target binding, which is why it often presents a lower incidence of peripheral neuropathy compared to first-generation inhibitors like bortezomib. Dosage and Administration Guidelines Administration: Kyprolis 60 mg is administered strictly via intravenous (IV) infusion by clinical professionals. Infusion Time: Depending on the dose and regimen, infusions typically last 10 minutes or 30 minutes. Cycle Intensity: Usually administered on two consecutive days each week for three weeks, followed by a 12-day rest period (28-day cycle). Pre-Treatment Hydration: Adequate oral and IV hydration is mandatory before and after the first cycle to prevent Tumor Lysis Syndrome (TLS) and protect renal function. Safety Profile and Professional Monitoring Cardiac & Pulmonary Health: Monitoring for signs of heart failure, hypertension, or pulmonary hypertension. Renal Function: Regular serum creatinine monitoring is essential, as the medication is processed through the kidneys. Hematological CBC: Periodic blood counts are necessary to manage potential thrombocytopenia (low platelets) or anemia. Common Side Effects: Fatigue, nausea, fever, headache, and diarrhea are frequently reported and managed with supportive care. Strict Cold-Chain Storage & Global Handling Temperature Sensitivity: Kyprolis is a sensitive biologic and MUST be stored refrigerated between 2°C and 8°C (36°F to 46°F). Handling: Do not freeze the vial. Keep it in the original carton to protect it from light. Logistical Security: For global export, we utilize validated thermal packaging and real-time data loggers to ensure the medication remains within the required temperature range throughout transit. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383